May. 1 at 6:50 AM
$COCH The Company has achieved full participation in the Acclaim study and initial participant data (below) has been very positive. Improved quality of life and hearing capability, no severe adverse side effects reported, participant uptime with new hearing aid 100% of the time, compared with 15.5/24.0 hr with current technology, wider range of use (swimming/exercise/sleep) and even tinnitus symptom reduction. This is a first-in-industry technology pending FDA approval from this study. The SP will likely linger in the interim, but there should come a day here (IMO) for multiplier upside if/where Acclaim ultimately delivers inline with the data accumulated to this point.
$0.60-0.80 consolidation with 5-10X upside (IMO) on study completion/success, FDA approval. 50-100% upside near term possible in the interim from this level.
https://finance.yahoo.com/sectors/healthcare/articles/envoy-medical-highlights-first-clinical-123000829.html?guccounter=1
